In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg

<p>Umoja Biopharma&apos;s CEO, Andy Scharenberg, M.D., joins Cell &amp; Gene: The Podcast&apos;s Erin Harris to discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics. They discuss The Climb, or The Colorado Laboratory and Innovation Manufacturing Building, which is Umoja’s lentiviral vector development and manufacturing facility. They also cover recent progress in lentiviral vector manufacturing.</p>